KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Assets (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Non-Current Assets readings, the most recent being $3.3 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 43.05% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.6 million, a 38.58% decrease, with the full-year FY2025 number at $3.3 million, down 43.05% from a year prior.
  • Non-Current Assets hit $3.3 million in Q4 2025 for Esperion Therapeutics, down from $3.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $54.6 million in Q3 2021 to a low of $1.2 million in Q1 2023.
  • Median Non-Current Assets over the past 5 years was $5.6 million (2021), compared with a mean of $16.5 million.
  • Biggest five-year swings in Non-Current Assets: soared 874.13% in 2022 and later crashed 97.67% in 2023.
  • Esperion Therapeutics' Non-Current Assets stood at $52.6 million in 2021, then plummeted by 97.61% to $1.3 million in 2022, then skyrocketed by 276.67% to $4.7 million in 2023, then grew by 23.08% to $5.8 million in 2024, then crashed by 43.05% to $3.3 million in 2025.
  • The last three reported values for Non-Current Assets were $3.3 million (Q4 2025), $3.6 million (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.